Biotek-snakken — September 2021
-
-
Biogen Announces Positive CHMP Opinion For VUMERITY - Quick Facts https://www.proinvestor.com/investornyt/705854/biogen-announces-positive-chmp-opinion-for-vumerity-quick-facts
-
Merck Gets Positive CHMP Opinion For
Keytruda Plus Chemotherapy For Triple-Negative Breast Cancer https://www.proinvestor.com/investornyt/705820/merck-gets-positive-chmp-opinion-for-keytruda-plus-chemotherapy-for-triple-negative-breast-cancer -
Corcept Therapeutics Presents Positive Results From Phase 2 Trial Of Relacorilant On Ovarian Cancer https://www.proinvestor.com/investornyt/705837/corcept-therapeutics-presents-positive-results-from-phase-2-trial-of-relacorilant-on-ovarian-cancer
-
Entasis fortalte forleden, at de roder med et nyt stof; ETX0462, som har fint potentiale. Fra artikel hedder det; "hold promise for the successful clinical development of the first novel Gram-negative chemotype to treat life-threatening antibiotic-resistant infections in more than 25 years". https://investors.entasistx.com/news-releases/news-release-details/profile-entasis-therapeutics-etx0462-candidate-published-journal
-
FDA Approves Exelixis' Cabometyx To Treat Metastatic Differentiated Thyroid Cancer https://www.proinvestor.com/investornyt/706237/fda-approves-exelixis-cabometyx-to-treat-metastatic-differentiated-thyroid-cancer
-
Pfizer: Xtandi Reduces Risk Of Death By 34% In Men With Metastatic Hormone-Sensitive Prostate Cancer https://www.proinvestor.com/investornyt/706234/pfizer-xtandi-reduces-risk-of-death-by-34-in-men-with-metastatic-hormone-sensitive-prostate-cancer
-
Brain+ IPO - De går foran med digital medicin mod demens og går efter en børsnotering https://www.youtube.com/watch?v=2mM9crR7jEM
-
5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch https://www.proinvestor.com/investornyt
/706252/5-covid-vaccine-stocks-with-late-stage-candidates-youll-want-to-watch -
Best Biotech Stocks To Buy Now? 4 For
Your Watchlist https://www.proinvestor.com/investornyt/706258/best-biotech-stocks-to-buy-now-4-for-your-watchlist -
AstraZeneca : Enhertu Shows Robust And Durable Tumor Response Of 54.9% In Patients With Lung Cancer https://www.proinvestor.com/investornyt/706290/astrazeneca-enhertu-shows-robust-and-durable-tumor-response-of-549-in-patients-with-lung-cancer
-
Exelixis Presents Results Of Cabozantinib On Metastatic Castration-Resistant Prostate Cancer https://www.proinvestor.com/investornyt/706294/exelixis-presents-results-of-cabozantinib-on-metastatic-castration-resistant-prostate-cancer
-
Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma https://www.proinvestor.com/investornyt/706298/mercks-keytruda-shows-recurrence-free-survival-in-resected-high-risk-stage-ii-melanoma
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind